Our CEO Kevin Hrusovsky joined Lyanne Alfaro on set of Nasdaq's
Resources by Therapeutic Area
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients.
Nurbhai S, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Ray KP, Reckless J, Mohammed H, Irving P, MacDonald TT, Vossenkamper A, West MR, Parkes GC and Crowe JS.
Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse
Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Yssel H, Garrido Castillo L, Cohen-Aubart F, Haroche J, Hié M, Pineton de Chambrun M, Miyara M, Pha M, Rozenberg F, Gorochov G and Amoura Z.
Nantes, France | November 12-14 | Booth 49
October 20-23 2019 | Vienna, Austria | Booth 2